KALV oral HAE therapy commercial traction

What happened: On April 29, KalVista Pharmaceuticals (NASDAQ:KALV) surged 38.62% to close at $26.67 after Italy's Chiesi Group agreed to acquire it for $27 per share in cash. KalVista's oral HAE therapy, EKTERLY, demonstrated strong early commercial traction, generating $35.4 million in Q4 and $49.1 million in net product revenue since launch. Humacyte reported 27 VAC approvals and orders from 27 hospitals for its product Symvess, generating $1.4 million in full-year product sales.

Market impact: The acquisition of KalVista by Chiesi Group is driving interest in the rare diseases sector, particularly around oral therapies. This deal, valued at approximately $1.1 billion, signals confidence in KalVista's pipeline and the broader potential of oral treatments for rare diseases. Investors are now watching for deal closing risks and regulatory approvals.

What to watch next: Key upcoming catalysts include the closing of the KalVista-Chiesi acquisition, expected in Q3 2023, and regulatory decisions around KalVista's pipeline. Additionally, investors should monitor Humacyte's progress with Symvess, particularly as it targets a pre-specified interim analysis for its ongoing clinical trial in the second half of 2023.